NewAmsterdam Pharma Co. NV (NAMS) Stock Price, Financials & Summary

Price chart

Sep 24Sep 29Oct 2Oct 7Oct 12Oct 15Oct 20Oct 23

Key dataOct 23, 2026

Open$21.39

From 52W high−52.45%

Volume2.31M

Market cap$2.36B

P/E (TTM)—

P/S (TTM)330.9x

Div yield—

Key dataOct 23, 2026

Open

$21.39

From 52W high

−52.45%

Volume

2.31M

Market cap

$2.36B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−6.8x

P/E (TTM)

—

RSI (14)

37.3

MomentumView details →

1D Return

−8.67%

YTD Return

−42.80%

SummaryUpdated Jun 1, 2026

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) is a clinical-stage biopharmaceutical company founded in 2019 and headquartered in Naarden, the Netherlands. The company went public in February 2021 and focuses on developing innovative treatments for metabolic diseases, particularly cardiovascular conditions related to cholesterol management. NewAmsterdam's primary focus is advancing its lead drug candidate through clinical trials to address unmet medical needs in cholesterol treatment and cardiovascular disease prevention.

Ask drillr about NewAmsterdam Pharma Co. NV →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−6.8x

EV/Sales

241.9x

P/S (TTM)

330.9x

P/B (TTM)

3.7x

ProfitabilityView details →

Gross Margin

92.15%

Net Margin

−3644.21%

EBITDA Margin

−3579.67%

ROE (TTM)

−41.10%

ROA (TTM)

−36.84%

Asset Turnover

0.01x

GrowthView details →

Revenue YoY

−88.87%

EPS YoY

−32.12%

FCF YoY

−15.62%

Revenue CAGR 3Y

−39.71%

EPS CAGR 3Y

+31.64%

EBITDA YoY

−32.54%

MomentumView details →

1D Return

−8.67%

YTD Return

−42.80%

1Y Return

−43.83%

RSI (14)

37.3

vs 50D SMA

−14.90%

vs 200D SMA

−33.40%

Capital & dividendView details →

Debt/Equity

0.00x

Current Ratio

9.03x

Quick Ratio

9.03x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.52

EPS Surprise

−7.90%

Beats (12Q)

2/12

Next Q EPS Est

−$0.45

Avg Surprise (4Q)

−15.06%

Rev Surprise

30.73%

Financials snapshotView financials →

Revenue (TTM)

7.12M

Net Income (TTM)

−259.50M

Op. CF (TTM)

−143.46M

Next earningsNov 4, 2026 →

Latest newsMore news →

NewAmsterdam Pharma dosed the first participant in its Phase 2b SPINOZA trial evaluating obicetrapib in adults with biomarker evidence of preclinical Alzheimer's disease.26d ago

The European Commission approved NewAmsterdam Pharma and Menarini Group's Ubeslo (obicetrapib monotherapy) and Evlarco (obicetrapib plus ezetimibe fixed-dose combination) in Europe.34d ago

Similar companies

Jiangsu Recbio Technology Co., Ltd.02179.HK 东亚药业605177.SH MBX Biosciences, Inc. Common StockMBX SELLAS Life Sciences Group, Inc.SLS ADMA Biologics, Inc.ADMA HJ Science Co., Ltd.06132.HK Find similar companies →

Latest newsMore news →

NewAmsterdam Pharma dosed the first participant in its Phase 2b SPINOZA trial evaluating obicetrapib in adults with biomarker evidence of preclinical Alzheimer's disease.26d ago The European Commission approved NewAmsterdam Pharma and Menarini Group's Ubeslo (obicetrapib monotherapy) and Evlarco (obicetrapib plus ezetimibe fixed-dose combination) in Europe.34d ago